In this large randomized , placebo-controlled trial among heterosexual persons , with median follow-up of @ months and maximum follow-up of @ months , daily oral TDF-based PrEP resulted in a small but nonprogressive decline in eGFR that was not accompanied by a substantial increase in the risk of clinically relevant ( @ % ) eGFR decline .